I mean raise capital on an overseas exchange in such a way that...

I mean raise capital on an overseas exchange in such a way that it re-values the company closer to fair value. It's an alternative to a partnership or buyout.

The process of pursuing external capital overseas would essentially be in competition to potential suitors that come knocking with partnership or buyout offers ( might encourage them to increase the money they are willing to commit ).

After readouts from Breast Cancer and AML trials in Australia, there are some paths the company could explore in addition to buyout:

• partnership with say a USD $100M upfront payment ( may be done as a partial equity investment )
• raise capital on an overseas exchange, say USD $100M

Aside from pools of capital competing with each other, both achieve the same purpose of maturing the drug towards approval and lift the value of RACE.

In the case of Juno the IPO which banked USD $265M was in December 2014.

The USD $1B partnership with Celgene then occurred 6 months later in June 2015.

The USD $9B buyout then occurred in January 2018. About 3 years after the IPO and 2.5 years after the partnership started.

https://www.fiercebiotech.com/r-d/updated-juno-banks-a-265m-ipo-pushing-next-big-thing-oncology

https://www.reuters.com/article/us-...ner-in-cancer-therapies-idUSKCN0P92OL20150629

https://www.fiercebiotech.com/biotech/celgene-confirms-9bn-juno-buyout-sees-3bn-sales-for-jcar017